Core Insights - The first domestic medical data product, "Analysis Report on the Association between Inflammation and Pulpitis," has been listed and traded on the Shanghai Data Exchange, marking a significant step towards the market-oriented allocation of medical data in China [1][2] - The data product is based on de-identified clinical data from Yuxiang Central Hospital, covering multiple dimensions such as imaging, pathology, genetic testing, and follow-up information, and has been processed and evaluated for quality by Shanghai Aopu Digital Creation Biotechnology Co., Ltd. [1] - The transaction signifies a complete cycle of rights confirmation, pricing, circulation, and revenue distribution for medical data as a new production factor, transitioning from "resource" to "asset" [1][2] Company and Industry Developments - Yuxiang Central Hospital views this listing as a milestone in its digital transformation and data asset management, aiming to enhance its data governance system and develop relevant small models to empower sustainable development in grassroots hospitals [2] - The transaction employs a "trusted data space" technology architecture to ensure data security and privacy, utilizing anonymization, de-identification, and encrypted transmission to protect original data [2] - The establishment of a trusted data space in Shanghai is seen as a key infrastructure to address the challenges of medical data sharing, facilitating the large-scale circulation of high-value medical data [2]